MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for MASH: phase 3 trial aims to shrink liver fat
Disease control Not yet recruitingThis study tests a new medicine called HSK31679 for people with MASH, a serious liver condition linked to metabolic issues. About 400 adults will receive either the drug or a placebo for 52 weeks to see if it safely reduces liver fat. The goal is to find a treatment that controls…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:44 UTC
-
Could a common body compound ease fatty liver damage?
Disease control Not yet recruitingThis study tests whether betaine, a natural substance found in the body, can reduce liver injury in people with MASH, a serious fatty liver disease. About 70 adults will take either betaine or a placebo pill daily for 24 weeks, and doctors will check their liver health through bl…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Southern California Institute for Research and Education • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo aims to reverse fatty liver damage in diabetics
Disease control Not yet recruitingThis study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting treatments, can help people with both type 2 diabetes and a serious fatty liver disease called MASH. About 300 adults will receive either the combination or a placebo to see i…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Exercise may help fight fatty liver in seniors, new study suggests
Knowledge-focused Not yet recruitingThis study looks at whether a 12-week exercise program can reduce liver fat, inflammation, and scarring in people with metabolic fatty liver disease. It compares results between older adults (70+) and middle-aged adults (40-60), as well as between those with mild and more advance…
Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Phase: NA • Sponsor: Consorcio Centro de Investigación Biomédica en Red (CIBER) • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC